Stem stock price forecast forward-looking stem stock price

Forward-looking stem stock price forecast models integrate macro health expenditure trends, anticipating expanded market adoption. Price target consensus holds firm at $19, contingent on consistent quarterly delivery from management. Moreover, its free cash flow is projected to grow from $69.4 million in 2024 to $540 million in 2029. If the cannabis stock trades at 10 times forward FCF, it could more than double within the next four years. Following the downgrade, the latest consensus from Stem's nine analysts is for revenues of US$160m in 2025, which would reflect a solid 11% improvement in sales compared to the last 12 months. Losses are predicted to fall substantially, shrinking 89% to US$0.60 per share. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$321m and losses of US$0.60 per share in 2025. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also making no real change to the loss per share numbers. Current stem stock price forecast data points to stable support levels at $15.50, driven by increased R&D investment in stem cell therapies. Market watchers cite FDA pipeline approvals as a key catalyst for sustained valuation strength heading into early